Showing results (101-110 of 214) with videos related to

Sort By:
Pageof 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2014
Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trialsPhilip A Philip, Kari Chansky, Michael LeBlanc, et al.
Nature Reviews. Clinical Oncology|March 18, 2023
Neoadjuvant therapy for pancreatic cancerChristoph Springfeld, Cristina R Ferrone, Matthew H G Katz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2013
First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinomaAndrew X Zhu, Philip J Gold, Anthony B El-Khoueiry, et al.
Pharmaceutical Research|April 28, 2010
Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancerSanjeev Banerjee, Asfar S Azmi, Subhash Padhye, et al.
Pancreas|April 21, 2004
Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell lineYiwei Li, Kerrie-Lynn Ellis, Shadan Ali, et al.
Plos One|March 17, 2011
Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancerBin Bao, Shadan Ali, Dejuan Kong, et al.
ISRN Oncology|October 30, 2013
Radiographic parameters in predicting outcome of patients with hepatocellular carcinoma treated with yttrium-90 microsphere radioembolizationMohamed E Salem, Nitin Jain, Gregory Dyson, et al.
Pancreas|December 25, 2002
Clinicopathologic analysis of pancreatic adenocarcinoma in African Americans and CaucasiansNat L Pernick, Fazlul H Sarkar, Philip A Philip, et al.
Medical Oncology (Northwood, London, England)|October 24, 2009
Clinicopathological analysis of primary epithelial appendiceal neoplasmsSachin Gupta, Venkata Parsa, Volkan Adsay, et al.
Cancer|July 13, 2012
Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trialsTodd M Bauer, Bassel F El-Rayes, Xiaobai Li, et al.
Pageof 22